Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMOHI-1: Mu-opiate Receptor Engagement in HIV-infected Opioid Use Disorder Patients
NCT04480554Phase 2Terminated
- Sponsor
- University of Pennsylvania
- Start
- Jan 2023
- Primary completion
- Jun 2025
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 2 trial of methadone, buprenorphine + naloxone, naltrexone in opioid use disorder (OUD), human immunodeficiency virus infection (HIV), sponsored by University of Pennsylvania. Started Jan 2023; status: terminated.
02
Drugs
methadonebuprenorphine + naloxonenaltrexone
03
Conditions
opioid use disorder (OUD)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04480554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480554.